Reframing Alzheimer’s Disease Through a Redox-Metabolic Framework
- 1Hospital Central de La Defensa “Gómez Ulla”, 28047 Madrid, Spain
- 2Department of Nursing, Physiotherapy and Medicine, University of Almería, 04120 Almería, Spain
- 3Food Technology Division, University of Almería, 04120 Almería, Spain
Abstract
Alzheimer’s disease (AD) has been conceptualised as a proteinopathy driven by amyloid-β plaques and hyperphosphorylated tau neurofibrillary tangles. AD should not be understood as exclusively a proteinopathy or a metabolic/redox disorder, but as a network of interacting processes in which metabolic dysfunction, mitochondrial impairment, redox dysregulation, amyloid-β, tau, neuroinflammation, metal dyshomeostasis, and regulated cell death reinforce one another. This review examines AD through a redox-metabolic framework integrating cerebral glucose metabolism, insulin signalling, mitochondrial bioenergetics, metal homeostasis, and regulated cell death. We discuss how glucose hypometabolism, impaired oxidative phosphorylation, and weakened antioxidant defences may promote reactive oxygen species production and self-reinforcing oxidative and metabolic dysfunction. We examine interactions with amyloid-β and tau pathology, glial immunometabolism, gut–brain signalling, neuroinflammation, and metal-mediated toxicity. Advances in multi-omics, blood-based metabolomic and lipidomic biomarkers, and imaging may enable earlier biological stratification. Therapeutic strategies targeting mitochondria, NRF2 signalling, metabolic dysfunction, metal dyshomeostasis, and regulated oxidative cell death are evaluated based on current evidence and their potential complementarity with amyloid-directed therapies. Although temporal relationships remain unresolved, redox-metabolic dysfunction may represent an early determinant and amplifier of neuronal vulnerability. Evidence for lecanemab and donanemab supports an integrative rather than replacement model of AD treatment. This framework may facilitate earlier diagnosis, patient stratification, and complementary disease-modifying interventions.
Related
- Alzheimer's disease risk gene Wwox controls amyloid pathology through metabolic reprogramming.
- Exploring healthy aging through preclinical Alzheimer disease in the Knight Alzheimer Research Imaging dataset
- Explainable AI framework for Alzheimer’s disease prediction using multimodal data
- Hippocampal and hypothalamic cell-type specific mechanisms underlying nutritional and metabolic modulation of Alzheimer’s disease
- A SynNotch-PiggyBac gene circuit for inflammation-responsive IL-10 delivery in Alzheimer’s disease: a hypothesis and design framework
BibTeX
@article{castrobono2026reframing,
title = {{Reframing Alzheimer’s Disease Through a Redox-Metabolic Framework}},
author = {Amador Velázquez De Castro-Bono and Gracia Castro-Luna and José Luis Guil-Guerrero},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = sep,
doi = {10.3390/ijms27188294},
url = {https://www.mdpi.com/1422-0067/27/18/8294},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Reframing Alzheimer’s Disease Through a Redox-Metabolic Framework
AU - Amador Velázquez De Castro-Bono
AU - Gracia Castro-Luna
AU - José Luis Guil-Guerrero
PY - 2026
DA - 2026/09/17
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27188294
UR - https://www.mdpi.com/1422-0067/27/18/8294
AB - Alzheimer’s disease (AD) has been conceptualised as a proteinopathy driven by amyloid-β plaques and hyperphosphorylated tau neurofibrillary tangles. AD should not be understood as exclusively a proteinopathy or a metabolic/redox disorder, but as a network of interacting processes in which metabolic dysfunction, mitochondrial impairment, redox dysregulation, amyloid-β, tau, neuroinflammation, metal dyshomeostasis, and regulated cell death reinforce one another. This review examines AD through a redox-metabolic framework integrating cerebral glucose metabolism, insulin signalling, mitochondrial bioenergetics, metal homeostasis, and regulated cell death. We discuss how glucose hypometabolism, impaired oxidative phosphorylation, and weakened antioxidant defences may promote reactive oxygen species production and self-reinforcing oxidative and metabolic dysfunction. We examine interactions with amyloid-β and tau pathology, glial immunometabolism, gut–brain signalling, neuroinflammation, and metal-mediated toxicity. Advances in multi-omics, blood-based metabolomic and lipidomic biomarkers, and imaging may enable earlier biological stratification. Therapeutic strategies targeting mitochondria, NRF2 signalling, metabolic dysfunction, metal dyshomeostasis, and regulated oxidative cell death are evaluated based on current evidence and their potential complementarity with amyloid-directed therapies. Although temporal relationships remain unresolved, redox-metabolic dysfunction may represent an early determinant and amplifier of neuronal vulnerability. Evidence for lecanemab and donanemab supports an integrative rather than replacement model of AD treatment. This framework may facilitate earlier diagnosis, patient stratification, and complementary disease-modifying interventions.
SN - 1422-0067
ER -